IL-33/ST2 signaling in monocyte-derived macrophages maintains blood-brain barrier integrity and restricts infarctions early after ischemic stroke
Authors:
Open Access
- 24 October 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 21 (1) , 1-14
Abstract
Brain microglia and infiltrating monocyte-derived macrophages are vital in preserving blood vessel integrity after stroke. Understanding mechanisms that induce immune cells to adopt vascular-protective phenotypes may hasten the development of stroke treatments. IL-33 is a potent chemokine released from damaged cells, such as CNS glia after stroke. The activation of IL-33/ST2 signaling has been shown to promote neuronal viability and white matter integrity after ischemic stroke. The impact of IL-33/ST2 on blood-brain barrier (BBB) integrity, however, remains unknown. The current study fills this gap and reveals a critical role of IL-33/ST2 signaling in macrophage-mediated BBB protection after stroke. Transient middle cerebral artery occlusion (tMCAO) was performed to induce ischemic stroke in wildtype (WT) versus ST2 knockout (KO) male mice. IL-33 was applied intranasally to tMCAO mice with or without dietary PLX5622 to deplete microglia/macrophages. ST2 KO versus WT bone marrow or macrophage cell transplantations were used to test the involvement of ST2+ macrophages in BBB integrity. Macrophages were cocultured in transwells with brain endothelial cells (ECs) after oxygen-glucose deprivation (OGD) to test potential direct effects of IL33-treated macrophages on the BBB in vitro. The ST2 receptor was expressed in brain ECs, microglia, and infiltrating macrophages. Global KO of ST2 led to more IgG extravasation and loss of ZO-1 in cerebral microvessels 3 days post-tMCAO. Intranasal IL-33 administration reduced BBB leakage and infarct severity in microglia/macrophage competent mice, but not in microglia/macrophage depleted mice. Worse BBB injury was observed after tMCAO in chimeric WT mice reconstituted with ST2 KO bone marrow, and in WT mice whose monocytes were replaced by ST2 KO monocytes. Macrophages treated with IL-33 reduced in vitro barrier leakage and maintained tight junction integrity after OGD. In contrast, IL-33 exerted minimal direct effects on the endothelial barrier in the absence of macrophages. IL-33-treated macrophages demonstrated transcriptional upregulation of an array of protective factors, suggesting a shift towards favorable phenotypes. Our results demonstrate that early-stage IL-33/ST2 signaling in infiltrating macrophages reduces the extent of acute BBB disruption after stroke. Intranasal IL-33 administration may represent a new strategy to reduce BBB leakage and infarct severity.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS131169)
- U.S. Department of Veterans Affairs (BX003651)
This publication has 44 references indexed in Scilit:
- Midline Shift Greater than 3 mm Independently Predicts Outcome After Ischemic StrokeNeurocritical Care, 2021
- IL‐33/ST2 axis deficiency exacerbates neutrophil‐dominant allergic airway inflammationClinical & Translational Immunology, 2021
- Efficient Strategies for Microglia Replacement in the Central Nervous SystemCell Reports, 2020
- Regulatory T cell is critical for interleukin-33-mediated neuroprotection against strokeExperimental Neurology, 2020
- The role of Interleukin-33 in the modulation of splenic T-cell immune responses after experimental ischemic strokeJournal of Neuroimmunology, 2019
- Evaluation of intranasal delivery route of drug administration for brain targetingBrain Research Bulletin, 2018
- Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammationBrain, Behavior, and Immunity, 2015
- RORC1 Regulates Tumor-Promoting “Emergency” Granulo-MonocytopoiesisCancer Cell, 2015
- Quantitative analysis of drug delivery to the brain via nasal routeJournal of Controlled Release, 2014
- Macrophages prevent hemorrhagic infarct transformation in murine stroke modelsAnnals of Neurology, 2012